At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, provides an update on the safety results of the phase 3 SABRINA study, which is comparing subcutaneous and intravenous rituximab in the maintenance setting of patients with follicular lymphoma.
>